link.springer.com
Genomics guiding personalized first-line immunotherapy response in lung and bladder tumors - Journal of Translational Medicine
Background Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment, particularly in advanced non-small cell lung cancer (NSCLC) and muscle-invasive bladder cancer (MIBC). However, iden...